Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIJAY-1: AUR104 in Relapsed/Refractory Lymphoid Malignancies
NCT06761586Phase 1Terminated
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XL114 in lymphoid malignancy, non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and 1 more, sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 1 year and 5 more. Started Dec 2024; status: terminated.
02
Drugs
XL114
03
Conditions
lymphoid malignancynon-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT06761586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761586.